Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study.
about
The Association between Sulfonylurea Use and All-Cause and Cardiovascular Mortality: A Meta-Analysis with Trial Sequential Analysis of Randomized Clinical TrialsCardiovascular Effect of Incretin-Based Therapy in Patients with Type 2 Diabetes Mellitus: Systematic Review and Meta-AnalysisPharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus.Obesity may attenuate the HbA1c-lowering effect of sitagliptin in Japanese type 2 diabetic patients.Randomized controlled clinical trial of a combination therapy of vildagliptin plus an α-glucosidase inhibitor for patients with type II diabetes mellitus.Efficacy and Safety of Vildagliptin as Add-on to Metformin in Japanese Patients with Type 2 Diabetes Mellitus.Use of Vildagliptin in Management of Type 2 Diabetes: Effectiveness, Treatment Persistence and Safety from the 2-Year Real-Life VILDA StudyComparative effectiveness of dipeptidylpeptidase-4 inhibitors in type 2 diabetes: a systematic review and mixed treatment comparisonThe effect of vildagliptin relative to sulphonylureas in Muslim patients with type 2 diabetes fasting during Ramadan: the VIRTUE study.Study to determine the durability of glycaemic control with early treatment with a vildagliptin-metformin combination regimen vs. standard-of-care metformin monotherapy-the VERIFY trial: a randomized double-blind trial.Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylureaAchieving glycemic control in elderly patients with type 2 diabetes: a critical comparison of current options.Clinical pharmacokinetics and pharmacodynamics of linagliptin.Higher Risk of Hypoglycemia with Glimepiride Versus Vildagliptin in Patients with Type 2 Diabetes is not Driven by High Doses of Glimepiride: Divergent Patient Susceptibilities?A real world comparison of sulfonylurea and insulin vs. incretin-based treatments in patients not controlled on prior metformin monotherapy.Effectiveness and tolerability of second-line treatment with vildagliptin versus other oral drugs for type 2 diabetes in a real-world setting in the Middle East: results from the EDGE studyComparison of vildagliptin-metformin and glimepiride-metformin treatments in type 2 diabetic patients.Comparative Efficacy of Adding Sitagliptin to Metformin, Sulfonylurea or Dual Therapy: A Propensity Score-Weighted Cohort Study.Hypoglycemia hospitalization frequency in patients with type 2 diabetes mellitus: a comparison of dipeptidyl peptidase 4 inhibitors and insulin secretagogues using the French health insurance database.Evidence to support the use of vildagliptin monotherapy in the treatment of type 2 diabetes mellitusLong-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study.Efficacy and tolerability of vildagliptin as first line treatment in patients with diabetes type 2 in an outpatient setting.Glimepiride: evidence-based facts, trends, and observations (GIFTS). [corrected]Utility of Saxagliptin in the Treatment of Type 2 Diabetes: Review of Efficacy and Safety.Efficacy and safety of vildagliptin in clinical practice-results of the PROVIL-study.Impact of insulin resistance, body mass index, disease duration, and duration of metformin use on the efficacy of vildagliptin.Achievement of recommended glucose and blood pressure targets in patients with type 2 diabetes and hypertension in clinical practice - study rationale and protocol of DIALOGUEProfile of vildagliptin in type 2 diabetes: efficacy, safety, and patient acceptability.Effects of vildagliptin relative to sulfonylureas in Muslim patients with type 2 diabetes fasting during Ramadan: influence of age and treatment with/without metformin in the VIRTUE study.Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin up-titration in Chinese patients with type 2 diabetes mellitus: study design and rationale of the vision studySafety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study.Effectiveness and safety of glimepiride and iDPP4, associated with metformin in second line pharmacotherapy of type 2 diabetes mellitus: systematic review and meta-analysis.Vildagliptin vs sulfonylurea in Indian Muslim diabetes patients fasting during RamadanExperience with Vildagliptin in Type 2 Diabetic Patients Fasting During Ramadan in France: Insights from the VERDI Study.Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes.A systematic literature review on the efficacy-effectiveness gap: comparison of randomized controlled trials and observational studies of glucose-lowering drugs.A randomized controlled clinical trial of vildagliptin plus metformin combination therapy in patients with type II diabetes mellitus.Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin.Incretin therapies in the management of elderly patients with type 2 diabetes mellitus.Review of the safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.
P2860
Q26748870-66ABB3FD-2AB5-4EC7-92DC-6C8088CCB65FQ28071764-26B877A8-968A-4FB5-A60D-1EF979A52576Q30249371-E7048F69-F934-4072-A17E-E990B731DC02Q33609811-25913DE6-C974-4A8C-A363-BA3EC1C7FFA3Q33706160-B6F16D9B-B3C8-4FF5-96A1-6BA5CA77240DQ33785117-7FAA0A8A-4A35-4069-A05A-CFDD26CCE535Q33785141-016C417B-D1A9-41B5-8937-821380EF1CCCQ33785197-909958AE-850A-4E7D-A524-42C71ED530D7Q34502809-F3D4CA17-A988-4B2B-96D2-CCA46DA15B24Q34516303-775DBFB4-6EC9-4921-878A-1FD0634CC533Q34543050-39A0AD03-4E49-4F0B-9A8C-F96185780D0DQ34563587-84E0BF10-0713-4D02-BE1C-880CA0511101Q34638128-FA78A64A-392B-4051-920E-AEE939488B00Q34726350-EFED45F1-8038-4566-B91C-B69B1807A013Q35073584-D69A91C3-AAB7-42C4-96EB-7E7F9EA95FEFQ35142675-39463950-8F97-47FD-BFFF-01FE72427E55Q35564083-2DA5C2AB-D4E6-4D83-86D0-8845B07592F9Q35772558-3D019C62-F8AC-4AB2-8367-A112885279E0Q35887463-6B35D275-7B09-41A7-9F89-A1AD657EF9F1Q35997324-2AF70466-BBE5-4DCA-82C4-58EA74137350Q36023385-F671DFFE-5BD9-4265-BD3A-4E471ECBF957Q36041081-61427A80-07AF-42B9-8947-6EC0211B9D11Q36251583-5133B3C9-7B25-4E85-B094-87E164F63ADFQ36327126-2B86DD91-F5E6-4D7C-9F92-E02CDB0B069DQ36365793-4D56DA34-E0A2-49BC-A421-103AEC188BAEQ36428052-17D2757E-8C28-4A48-B693-B59323856DCCQ36510353-585B4EA0-C672-4428-B8E3-BF3CBDD6CB78Q36960161-86785A75-F2D4-499D-8DC9-DFB3FBE6BC62Q37142980-EAF7E5C7-DEE7-4D4F-855C-068D3D400506Q37153711-B0FDF694-DFD3-4EDF-8B94-2EF54A39BCFBQ37225065-4ECF8F12-1798-4214-A1E8-2E7AE7F4CDC8Q37257372-FB2D4E51-FC85-4EDD-A13D-A15C62B5392DQ37417767-04556416-C18E-41C1-8BDD-2ACE230411D3Q37468458-E0E168FC-A391-47BC-854E-3EC5C1396391Q37577162-48D6B798-2490-4DAD-B2B7-ADC73739EAD9Q37610459-EEF6FB07-DFAE-4F54-9ED4-A752D5F9F3C4Q37652091-93957BA3-9D00-448D-BDA5-A160F3E2F16BQ37825941-5A7560B4-39A1-43FE-A30E-3EBE4F108F9EQ37858364-69C8FFE9-4EA9-4DA4-AD4B-5BD30C194980Q37890793-5B8F7103-AC38-468B-9DA7-9AD47275E55A
P2860
Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Vildagliptin add-on to metform ...... : results from a 2-year study.
@en
Vildagliptin add-on to metform ...... : results from a 2-year study.
@nl
type
label
Vildagliptin add-on to metform ...... : results from a 2-year study.
@en
Vildagliptin add-on to metform ...... : results from a 2-year study.
@nl
prefLabel
Vildagliptin add-on to metform ...... : results from a 2-year study.
@en
Vildagliptin add-on to metform ...... : results from a 2-year study.
@nl
P2093
P1476
Vildagliptin add-on to metform ...... : results from a 2-year study.
@en
P2093
A Couturier
D R Matthews
E Ferrannini
P304
P356
10.1111/J.1463-1326.2010.01233.X
P50
P577
2010-09-01T00:00:00Z